Craig L Tendler, M.D.
Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development (Retired)
In this position, Craig was responsible for creating and overseeing robust development plans, including optimal integration of biomarkers and diagnostics, as well as comprehensive data generation activities for all products in the oncology portfolio, from proof of concept through registration and lifecycle management. He worked closely with teams in early development and disease areas of focus to implement a seamless end-to-end oncology clinical research strategy that incorporated compelling science, broad clinical trial access to diverse populations, and addressed areas of high unmet medical need.
Craig has overseen and coordinated > 30 major drug approvals by national regulatory agencies, including 15 NDAs by the US Food and Drug Administration (FDA). He and his team worked in collaboration with the FDA and the European Medicines Agency to secure worldwide approvals for J&J’s transformational treatments in prostate cancer (ZYTIGA, AKEEGA, ERLEADA), hematologic malignancies (DARZALEX, CARVYKTI, TECVAYLI, TALVEY, IMBRUVICA), as well as lung (RYBREVANT) and bladder cancer (BALVERSA). Together with his team, Craig has been instrumental in achieving 13 FDA breakthrough designations for accelerating the early development of promising investigational medicines intended for the treatment of serious oncology conditions.
In addition to his pharmaceutical industry experience, Craig has served as Co-Chair of the Friends of Cancer Research Corporate Council, member of the Bloomberg New Economy International Cancer Coalition, and member of the Admissions Committee at Mount Sinai School of Medicine. He was an Assistant Professor of Pediatrics/Hematology-Oncology at Mount Sinai School of Medicine and a NIH physician-scientist grant recipient and research fellow at the National Cancer Institute in Bethesda, Maryland.
Craig earned his undergraduate degree from Cornell University and graduated from the Mount Sinai School of Medicine in New York City with high honors and induction into the Alpha Omega Alpha Medical Society.